-
Read ArticleA new option for hard-to-treat ovarian cancer is being evaluated
Providence Cancer Institute is enrolling patients in a clinical trial to test Mo-Rez.
-
Read ArticleWhen eating is difficult: How to get good nutrition during cancer treatment
Providence Cancer Institute dietitian answers questions and offers helpful tips.
-
Read ArticleNew study evaluates a medication for NSCLC with the KRAS G12C mutation
Many people with advanced NSCLC still need better treatment options. This study is evaluating an investigational medication that may help them live longer.
-
Read ArticleRestoring intimacy after cancer: One woman’s story
A sexual health professional at Providence helped Ellen regain her sense of self after treatment for endometrial cancer.
-
Read ArticleDark genome, bright outcome: A first-of-its-kind trial gives Del Abbott a second chance
Del survived Arctic winters, a demanding career and cancer – twice. Here’s how a pioneering Providence Cancer Institute trial helped him beat it a second time.
-
Read ArticleA new liver cancer trial explores a “two-in-one" treatment approach
Providence Cancer Institute is enrolling patients with hepatocellular carcinoma in a trial of pumitamig, an investigational bispecific antibody.
-
Read ArticleProvidence Cancer Institute secures three significant grants
Prestigious grants will help researchers pursue important cancer studies.
-
Read ArticleQ&A: Meet one of the investigational drug pharmacists at Providence
An inside look at how a pharmacist at Providence Cancer Institute keeps clinical trials running safely, one dose at a time.
-
Read ArticleNew T-cell therapy for KRAS G12D cancers
An expanded access program uses engineered T cells to target the KRAS G12D mutation in pancreatic, colorectal or other advanced cancers.
-
Read ArticleWhen standard treatment isn’t enough: A new study offers hope for people with triple-negative breast cancer
A new clinical trial is testing a promising drug combination that could improve survival for people whose cancer didn’t fully respond to standard treatment.
-
Read ArticleHope comes in a clinical trial: Brad’s remarkable story
When Brad’s medullary thyroid cancer returned after a surgical procedure, he enrolled in a clinical trial. Now, his cancer is nearly undetectable.
-
Read ArticleProvidence researchers head to Chicago for leading cancer conference
Researchers at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, are helping shape the future of cancer care at the 2026 ASCO Annual Meeting in Chicago.
-
Read ArticleAdoptive cell therapy: Phase III study open for people with advanced melanoma
Inside the IMA203 phase III trial enrolling patients at Providence Cancer Institute.
-
Read ArticleIt started with one bandage, and a patient’s smile
How novelty bandages have become a beloved tradition at Providence Cancer Institute Newberg Clinic.
-
Read ArticleNew guidelines for treating head and neck cancer could be a game changer
New ASCO guidelines are designed to make the full body of evidence accessible to clinicians across specialties, including those who may not work routinely with a head and neck surgeon.
-
Read ArticlePioneering immunotherapy clinical trial enrolling patients with advanced cancers
A new medication called M3T01, developed at Providence Cancer Institute, takes a different approach to immunotherapy.
-
Read ArticleVOICES of Black Women: A community study in cancer prevention and care
A new study focused on stories will change health outcomes for Black women.
-
Read ArticleLeading the way: Providence researchers at AACR Annual Meeting
The annual AACR meeting draws the most innovative cancer researchers seeking breakthroughs in treatments.
-
Read ArticleA quiet lifeline: Meet the volunteer at Jill Lematta Learning Center
Cancer resources and compassion are plentiful in a quiet space at Providence Cancer Institute Franz Clinic.
-
Read ArticleGene therapy shows promising results against multiple myeloma
This study is now enrolling patients at Providence Cancer Institute – the only site outside of Australia.
-
Loading More...


